Cancer Chemotherapy-Related Symptoms: Evidence to Suggest a Role for Proinflammatory Cytokines

Lisa J. Wood

Lillian M. Nail

April Gilster

Kerri A. Winters

Collin R. Elsea

ONF 2007, 33(3), 535-542. DOI: 10.1188/06.ONF.535-542
Download PDF

Purpose/Objectives: To provide an overview of the evidence that supports a role for the proinflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in the etiology of cancer chemotherapy-related symptoms.

Data Sources: Electronic nursing, psychology, and medicine databases; online meeting abstracts; and personal experimental observations.

Data Synthesis: Substantial evidence implicates the proinflammatory cytokines IL-1β, TNF-α, and IL-6 in the etiology of chemotherapy-related anorexia, cachexia, anemia, pain, sleep disturbance, fatigue, and depression.

Conclusions: Further investigation into the role of these cytokines in the genesis of chemotherapy-related symptoms is warranted. The development of appropriate animal models likely will be key to under-standing the relationship among cancer chemotherapy, proinflammatory cytokines, and symptoms.

Implications for Nursing: Nurses traditionally have been leaders in symptom management. The symptoms experienced by patients under-going chemotherapy have a profound negative impact on quality of life and patients' ability to receive prescribed treatments. An understanding of potential mechanisms underlying the physiologic and behavioral consequences of chemotherapy administration will aid nurses in the development of interventions to effectively manage chemotherapy-related symptoms.

Jump to a section

    References

    Ancoli-Israel, S., Moore, P.J., & Jones, V. (2001). The relationship between fatigue and sleep in cancer patients: A review. European Journal of Cancer Care, 10, 245-255.
    Anderson, K.O., Getto, C.J., Mendoza, T.R., Palmer, S.N., Wang, X.S., Reyes-Gibby, C.C., et al. (2003). Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. Journal of Pain and Symptom Management, 25, 307-318.
    Anisman, H., Merali, Z., Poulter, M.O., & Hayley, S. (2005). Cytokines as a precipitant of depressive illness: Animal and human studies. Current Pharmaceutical Design, 11, 963-972.
    Argiles, J.M., Busquets, S., & Lopez-Soriano, F.J. (2005). The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 37, 2036-2046.
    Badger, A.M., Bradbeer, J.N., Votta, B., Lee, J.C., Adams, J.L., & Griswold, D.E. (1996). Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. Journal of Pharmacology and Experimental Therapeutics, 279, 1453-1461.
    Berger, A.M. (1998). Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncology Nursing Forum, 25, 51-62.
    Berger, A.M., & Farr, L. (1999). The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncology Nursing Forum, 26, 1663-1671.
    Berger, A.M., & Higginbotham, P. (2000). Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncology Nursing Forum, 27, 1443-1448.
    Berger, A.M., VonEssen, S., Kuhn, B.R., Piper, B.F., Agrawal, S., Lynch, J.C., et al. (2003). Adherence, sleep, and fatigue outcomes after adjuvant breast cancer chemotherapy: Results of a feasibility intervention study. Oncology Nursing Forum, 30, 513-522.
    Bernard, S., Gill, P., Rosen, P., Gavigan, M., Steagall, A., Ellingham, E., et al. (1991). A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Medical and Pediatric Oncology, 19, 276-282.
    Bluthe, R.M., Laye, S., Michaud, B., Combe, C., Dantzer, R., & Parnet, P. (2000). Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: A study with interleukin-1 type I receptor-deficient mice. European Journal of Neuroscience, 12, 4447-4456.
    Bluthe, R.M., Michaud, B., Poli, V., & Dantzer, R. (2000). Role of IL-6 in cytokine-induced sickness behavior: A study with IL-6 deficient mice. Physiology and Behavior, 70, 367-373.
    Bogdan, C., & Ding, A. (1992). Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. Journal of Leukocyte Biology, 52, 119-121.
    Branger, J., van den Blink, B., Weijer, S., Madwed, J., Bos, C.L., Gupta, A., et al. (2002). Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Journal of Immunology, 168, 4070-4077.
    Cahlin, C., Korner, A., Axelsson, H., Wang, W., Lundholm, K., & Svanberg, E. (2000). Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Research, 60, 5488-5493.
    Capuron, L., Ravaud, A., Miller, A.H., & Dantzer, R. (2004). Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain, Behavior, and Immunity, 18, 205-213.
    Carpenter, J.S., Elam, J.L., Ridner, S.H., Carney, P.H., Cherry, G.J., & Cucullu, H.L. (2004). Sleep, fatigue, and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncology Nursing Forum, 31, 591-598.
    Chao, C.C., DeLaHunt, M., Hu, S., Close, K., & Peterson, P.K. (1992). Immunologically mediated fatigue: A murine model. Clinical Immunology and Immunopathology, 64, 161-165.
    Curt, G.A., Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist, 5, 353-360.
    Dantzer, R. (2004a). Cytokine-induced sickness behaviour: A neuroimmune response to activation of innate immunity. European Journal of Pharmacology, 500, 399-411.
    Dantzer, R. (2004b). Innate immunity at the forefront of psychoneuroimmunology. Brain, Behavior, and Immunity, 18, 1-6.
    Dantzer, R., Aubert, A., Bluthe, R.M., Gheusi, G., Cremona, S., Laye, S., et al. (1999). Mechanisms of the behavioural effects of cytokines. Advances in Experimental Medicine and Biology, 461, 83-105.
    Davidson, J.R., MacLean, A.W., Brundage, M.D., & Schulze, K. (2002). Sleep disturbance in cancer patients. Social Science and Medicine, 54, 1309-1321.
    Ding, A.H., Porteu, F., Sanchez, E., & Nathan, C.F. (1990). Shared actions of endotoxin and Taxol on TNF receptors and TNF release. Science, 248, 370-372.
    Dropcho, E.J. (2004). Neurotoxicity of cancer chemotherapy. Seminars in Neurology, 24, 419-426.
    Elsea, C.R., Nail, L.M., Druker, B.J., & Wood, L.J. (2006). Induction of IL-1β, TNF-α, and IL-6 production by mechanistically distinct cancer chemotherapy drugs in macrophages: The role of p38 MAPK & JNK. Unpublished manuscript.
    Enomoto, A., Rho, M.C., Fukami, A., Hiraku, O., Komiyama, K., & Hayashi, M. (2004). Suppression of cancer cachexia by 20S, 21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochemical and Biophysical Research Communications, 323, 1096-1102.
    Ferrell, B.R., Grant, M., Funk, B., Garcia, N., Otis-Green, S., & Schaffner, M.L. (1996). Quality of life in breast cancer. Cancer Practice, 4, 331-340.
    Glaus, A. (1998). Fatigue in patients with cancer. Analysis and assessment. Recent Results in Cancer Research, 145, I-XI, 1-172.
    Goldblatt, F., & Isenberg, D.A. (2005). New therapies for rheumatoid arthritis. Clinical and Experimental Immunology, 140, 195-204.
    Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
    Haldar, S., Basu, A., & Croce, C.M. (1997). Bc12 is the guardian of microtubule integrity. Cancer Research, 57, 229-233.
    Hentze, M.W., Muckenthaler, M.U., & Andrews, N.C. (2004). Balancing acts: Molecular control of mammalian iron metabolism. Cell, 117, 285-297.
    Hill, A.G., Siegel, J., Rounds, J., & Wilmore, D.W. (1997). Metabolic responses to interleukin-1: Centrally and peripherally mediated. Annals of Surgery, 225, 246-251.
    Jelkmann, W., Pagel, H., Wolff, M., & Fandrey, J. (1992). Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sciences, 50, 301-308.
    Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005). Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 106, 1864-1866.
    Kent, S., Bret-Dibat, J.L., Kelley, K.W., & Dantzer, R. (1996). Mechanisms of sickness-induced decreases in food-motivated behavior. Neuroscience and Biobehavioral Reviews, 20(1), 171-175.
    Knight, K., Wade, S., & Balducci, L. (2004). Prevalence and outcomes of anemia in cancer: A systematic review of the literature. American Journal of Medicine, 116(Suppl. 7A), 11S-26S.
    Kozak, W., Kluger, M.J., Soszynski, D., Conn, C.A., Rudolph, K., Leon, L.R., et al. (1998). IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Annals of the New York Academy of Sciences, 856, 33-47.
    Krueger, J.M., & Majde, J.A. (1994). Microbial products and cytokines in sleep and fever regulation. Critical Reviews in Immunology, 14, 355-379.
    Krueger, J.M., Obal, F.J., Fang, J., Kubota, T., & Taishi, P. (2001). The role of cytokines in physiological sleep regulation. Annals of the New York Academy of Sciences, 933, 211-221.
    Laviano, A., Cangiano, C., Fava, A., Muscaritoli, M., Mulieri, G., & Rossi Fanelli, F. (1999). Peripherally injected IL-1 induces anorexia and increases brain tryptophan concentrations. Advances in Experimental Medicine and Biology, 467, 105-108.
    Lee, B.N., Dantzer, R., Langley, K.E., Bennett, G.J., Dougherty, P.M., Dunn, A.J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11, 279-292.
    Lee, K., Cho, M., Miaskowski, C., & Dodd, M. (2004). Impaired sleep and rhythms in persons with cancer. Sleep Medicine Reviews, 8, 199-212.
    Lee, K.A. (2001). Sleep and fatigue. Annual Review of Nursing Research, 19, 249-273.
    Lyczak, J.B. (2004). Innate immunity. In G.B. Pier, J.B. Lyczak, & M. Wetzler (Eds.), Immunology, infection, and immunity. Washington, DC: ASM Press.
    Macdougall, I.C., & Cooper, A.C. (2002). Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrology, Dialysis, and Transplantation, 17(Suppl. 11), 39-43.
    McCarthy, D.O. (2000). Tumor necrosis factor alpha and interleukin-6 have differential effects on food intake and gastric emptying in fasted rats. Research in Nursing Health, 23, 222-228.
    Means, R.T. (2004). Hepcidin and cytokines in anaemia. Hematology, 9, 357-362.
    Mercadante, S., Gebbia, V., Marrazzo, A., & Filosto, S. (2000). Anaemia in cancer: Pathophysiology and treatment. Cancer Treatment Reviews, 26, 303-311.
    Mercadante, S., Girelli, D., & Casuccio, A. (2004). Sleep disorders in advanced cancer patients: Prevalence and factors associated. Supportive Care in Cancer, 12, 355-359.
    Mock, V., Atkinson, A., Barsevick, A., Cella, D., Cimprich, B., Cleeland, C., et al. (2003). Cancer-related fatigue clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 1, 308-331.
    Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., et al. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine, 344, 961-966.
    Nail, L.M., & Winningham, M.L. (1995). Fatigue and weakness in cancer patients: The symptoms experience. Seminars in Oncology Nursing, 11, 272-278.
    Nakamura, Y., Shimizu, H., Nishijima, C., Ueno, M., & Arakawa, Y. (2001). Delayed functional recovery by vincristine after sciatic nerve crush injury: A mouse model of vincristine neurotoxicity. Neuroscience Letters, 304(1-2), 5-8.
    Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., et al. (2005). Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 106, 2627-2632.
    Ocean, A.J., & Vahdat, L.T. (2004). Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer, 12, 619-625.
    Ogawa, T., Mimura, Y., Isowa, K., Kato, H., Mitsuishi, M., Toyoshi, T., et al. (2001). An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicology Letters, 121(2), 97-106.
    Okereke, O.I. (2002). Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. Psychosomatics, 43, 237-240.
    Olson, J.M., & Hallahan, A.R. (2004). p38 MAP kinase: A convergence point in cancer therapy. Trends in Molecular Medicine, 10, 125-129.
    Olson, K., Tom, B., Hewitt, J., Whittingham, J., Buchanan, L., & Ganton, G. (2002). Evolving routines: Preventing fatigue associated with lung and colorectal cancer. Qualitative Health Research, 12, 655-670.
    Omdal, R., & Gunnarsson, R. (2004). The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—A pilot study. Rheumatology International, 25, 481-484.
    Ottenweller, J.E., Natelson, B.H., Gause, W.C., Carroll, K.K., Beldowicz, D., Zhou, X.D., et al. (1998). Mouse running activity is lowered by Brucella abortus treatment: A potential model to study chronic fatigue. Physiology and Behavior, 63, 795-801.
    Ozturk, G., Erdogan, E., Anlar, O., Kosem, M., & Taspinar, M. (2005). Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine, 29, 31-41.
    Pasparakis, M., Alexopoulou, L., Episkopou, V., & Kollias, G. (1996). Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. Journal of Experimental Medicine, 184, 1397-1411.
    Piper, B.F. (1990). Piper Fatigue Scale available for clinical testing. Oncology Nursing Forum, 17, 661-662.
    Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., et al. (1994). Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO Journal, 13, 1189-1196.
    Polomano, R.C., Mannes, A.J., Clark, U.S., & Bennett, G.J. (2001). A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain, 94, 293-304.
    Purswani, M.U., Eckert, S.J., Arora, H.K., & Noel, G.J. (2002). Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. Journal of Antimicrobial Chemotherapy, 50, 51-58.
    Pusztai, L., Mendoza, T.R., Reuben, J.M., Martinez, M.M., Willey, J.S., Lara, J., et al. (2004). Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine, 25, 94-102.
    Roux, P.P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews, 68, 320-344.
    Schaefer, M., Horn, M., Schmidt, F., Schmid-Wendtner, M.H., Volkenandt, M., Ackenheil, M., et al. (2004). Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain, Behavior, and Immunity, 18, 555-562.
    Schaefer, M., Schmidt, F., Horn, M., Schmid-Wendtner, M.H., & Volkenandt, M. (2004). Depression during treatment with interferon alpha. Psychosomatics, 45, 176.
    Scheibel, R.S., Valentine, A.D., O'Brien, S., & Meyers, C.A. (2004). Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. Journal of Neuropsychiatry and Clinical Neuroscience, 16, 185-191.
    Schwartz, A.L. (2000). Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Practice, 8, 16-24.
    Schwartz, A.L., Nail, L.M., Chen, S., Meek, P., Barsevick, A.M., King, M.E., et al. (2000). Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Investigations, 18, 11-19.
    Segreti, J., Gheusi, G., Dantzer, R., Kelley, K.W., & Johnson, R.W. (1997). Defect in interleukin-1 beta secretion prevents sickness behavior in C3H/HeJ mice. Physiology and Behavior, 61, 873-878.
    Sheng, W.S., Hu, S., Ding, J.M., Chao, C.C., & Peterson, P.K. (2001). Cytokine expression in the mouse brain in response to immune activation by Corynebacterium parvum. Clinical and Diagnostic Laboratory Immunology, 8, 446-448.
    Sheng, W.S., Hu, S., Lamkin, A., Peterson, P.K., & Chao, C.C. (1996). Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clinical Immunology and Immunopathology, 81, 161-167.
    Sommer, C., & Kress, M. (2004). Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neuroscience Letters, 361(1-3), 184-187.
    ten Tije, A.J., Smorenburg, C.H., Seynaeve, C., Sparreboom, A., Schothorst, K.L., Kerkhofs, L.G., et al. (2004). Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. European Journal of Cancer, 40, 352-357.
    Testa, U. (2004). Apoptotic mechanisms in the control of erythropoiesis. Leukemia, 18, 1176-1199.
    Thomas, A.J., Davis, S., Morris, C., Jackson, E., Harrison, R., & O'Brien, J.T. (2005). Increase in interleukin-1beta in late-life depression. American Journal of Psychiatry, 162, 175-177.
    Tisdale, M.J. (2004). Cancer cachexia. Langenbeck's Archives of Surgery, 389, 299-305.
    Trask, P.C., Paterson, A.G., Esper, P., Pau, J., & Redman, B. (2004). Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psycho-Oncology, 13, 526-536.
    Tuglu, C., Kara, S.H., Caliyurt, O., Vardar, E., & Abay, E. (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology, 170, 429-433.
    Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Kales, A., Tyson, K., & Chrousos, G.P. (1997). Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity. Journal of Clinical Endocrinology and Metabolism, 82, 1313-1316.
    Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Lotsikas, A., Zachman, K., Kales, A., et al. (1999). Circadian interleukin-6 secretion and quantity and depth of sleep. Journal of Clinical Endocrinology and Metabolism, 84, 2603-2607.
    Vgontzas, A.N., Zoumakis, E., Bixler, E.O., Lin, H.M., Follett, H., Kales, A., et al. (2004). Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. Journal of Clinical Endocrinology and Metabolism, 89, 2119-2126.
    Vogelzang, N.J., Breitbart, W., Cella, D., Curt, G.A., Groopman, J.E., Horning, S.J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Seminars in Hematology, 34(3, Suppl. 2), 4-12.
    Waterston, A., & Bower, M. (2004). Fifty years of multicentric Castleman's disease. Acta Oncologica, 43, 698-704.
    Watkins, L.R., Goehler, L.E., Relton, J., Brewer, M.T., & Maier, S.F. (1995). Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Research, 692, 244-250.
    Weinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A., et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis and Rheumatism, 48, 35-45.
    Winningham, M.L., Nail, L.M., Burke, M.B., Brophy, L., Cimprich, B., Jones, L.S., et al. (1994). Fatigue and the cancer experience: The state of the knowledge. Oncology Nursing Forum, 21, 23-36.
    Wood, L.J., Nail, L.M., Perrin, N.A., Elsea, C.R., Fischer, A., & Druker, B.J. (in press). The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy related symptoms. Biological Research for Nursing, 7(4).
    Woolf, C.J., Allchorne, A., Safieh-Garabedian, B., & Poole, S. (1997). Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor alpha. British Journal of Pharmacology, 121, 417-424.
    Zaki, M.H., Nemeth, J.A., & Trikha, M. (2004). CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. International Journal of Cancer, 111, 592-595.
    Zhong, J., Dietzel, I.D., Wahle, P., Kopf, M., & Heumann, R. (1999). Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. Journal of Neuroscience, 19, 4305-4313.